McAfee Receives AV-Comparatives Gold Awards for Best Real-World Protection and Best Performance Throughout 2024
20.1.2025 14:00:00 CET | Business Wire | Press release
Coveted awards celebrate McAfee for providing powerful malware protection without slowing down PCs
McAfee, a global online protection leader, today announced that it has been recognized by AV-Comparatives with both the ‘Real-World Protection Gold Award’ and the ‘Best Overall Speed Gold Award’. These honors spotlight McAfee’s unmatched ability to deliver top-tier malware protection to consumers while improving PC performance, as demonstrated in AV-Comparatives’ 2024 test results.
McAfee was one of only six vendors to achieve top overall results in the 2024 Real-World Protection tests, while also ranking as the vendor with the lowest impact on PC performance throughout 2024. This means that by replacing the protection that comes with your PC’s operating system, McAfee can improve the overall performance of a PC.
This is particularly important at a time when bad actors are leveraging rapidly evolving and increasingly sophisticated tools to target victims.
Throughout the year, the AV-Comparatives Lab team rigorously tests leading consumer security products and evaluates them in terms of protection, and impact on PC performance.
- McAfee’s win in the Real-World Protection Test points to an ability to offer exceptional malware protection in everyday online conditions, as tested by AV-Comparatives. This recognition highlights McAfee’s success in providing a high level of protection with minimal false alarms; this ensures consumers are protected without the burden of discerning whether or not something is harmful.
- McAfee’s top rank in the PC Performance Test reflects its strength, as tested by AV-Comparatives, in delivering powerful security without slowing down system performance. This critical metric aligns with McAfee’s consumer-first focus, ensuring that consumers stay protected while their PCs run efficiently at top speed.
“We are honored to receive both the Best Real-World Protection and the Best PC Performance awards,” said Steve Grobman, Chief Technology Officer, McAfee. “AV-Comparatives’ trusted analysis validates our success in developing technology that protects people while improving device performance. We are committed to giving consumers the education and tools they need to stay safe online while maintaining performance and ensuring that our protection evolves as quickly as the threat landscape.”
Those interested in protecting themselves and their families online with this year’s top-rated security software can download a free trial of McAfee Total Protection. This includes the company’s award-winning anti-malware technology, as well as scam detection, social privacy management, identity monitoring, Secure VPN, password management, and safe browsing capabilities for all-in-one protection.
McAfee’s award-winning, AI-powered anti-malware technology is included in McAfee Total Protection, McAfee+ Premium, McAfee+ Advanced, and McAfee+ Ultimate.
You can learn more about McAfee’s awards and recognition from AV-Comparatives here.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.McAfee.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120474901/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom